LEM-S401 / Lemonex - LARVOL DELTA

A First-In-Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM-S401, a Novel siRNA-DegradaBALL Drug Targeting CTGF in Healthy Adults. (PubMed, Clin Transl Sci) - P1 | "Trial Registration: ClinicalTrials.gov identifier: NCT04707131. https://clinicaltrials.gov/study/NCT04707131?cond=NCT04707131&rank=1."

Clinical • Journal • P1 data • Dermatology • Fibrosis • Immunology • Pain • CTGF

A Study of Single Ascending Dose of LEM-S401 in Healthy Participants (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Lemonex Inc. | Recruiting ➔ Completed

Trial completion

A Study of Single Ascending Dose of LEM-S401 in Healthy Participants (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Lemonex Inc. | Not yet recruiting ➔ Recruiting

Enrollment open